CytoDyn Granted Small Business Waiver of Application Fees by FDA for Leronlimab (PRO 140) BLA Filing Aug 05, 2019 6:00am EDT
CytoDyn Sponsored Research Reaffirms the Role of CCR5 in Cancer Biology and Provides a New Potential Cancer Treatment Modality Aug 02, 2019 6:00am EDT
CytoDyn Executes Exclusive Worldwide Licensing Agreement with IncellDX for PA-14 and PRO 140 for Diagnostic Testing Purposes Jul 26, 2019 6:00am EDT
CytoDyn Finalizes Development of Receptor Occupancy Test to Guide Pivotal Monotherapy Discussions With the FDA Jul 25, 2019 6:00am EDT
CytoDyn Names Dr. Jonah Sacha as its Senior Science Advisor to Explore Leronlimab (PRO 140) Potentials in HIV Pre-Exposure Prophylaxis (PrEP) and Cure Jul 08, 2019 6:00am EDT
CytoDyn Anticipates Revenue Commencing in August 2019 from Use of PA-14 and/or PRO 140 in Diagnostic Test Jul 01, 2019 6:00am EDT
FDA Grants Face-to-Face Meeting to Discuss CytoDyn’s 510(k) Application for ProstaGene™ Prognostic Test Jun 24, 2019 6:00am EDT
CytoDyn Submits 510(k) Pre-Submission Application to U.S. FDA for ProstaGene™ Prognostic Test Jun 19, 2019 9:02am EDT
CytoDyn Signs Groundbreaking Memorandum of Understanding with Thai Red Cross AIDS Research Centre to Study Pre-Exposure Prophylaxis Use of Leronlimab (PRO 140) in People at High Risk of Acquiring HIV Jun 17, 2019 6:00am EDT
